CRISPR-engineered T cells in Patients with Refractory Cancer

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published in Science by researchers from the Abramson Cancer Center.

CRISPR-engineered T cells in patients with refractory cancer

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Penn study shows potential of interferon pathway as biomarker, therapeutic target

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Analysis of the Evolution of CAR T-cell Immunotherapy through Patenting Activity

Nature Biotechnology review of emerging technology of chimeric antigen receptor (CAR) T-cell immunotherapy shows six of the top 20 global CAR-T inventors are from Penn.

Penn's Gene Therapy Startup Raises Another $50 Million

Funding for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions.